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Abstract
In the absence of effective vaccine(s), control of African swine fever caused by African
swine fever virus (ASFV) must be based on early, efficient, cost-effective detection and
strict control and elimination strategies. For this purpose, we developed an indirect ELISA
capable of detecting ASFV antibodies in either serum or oral fluid specimens. The recombi-
nant protein used in the ELISA was selected by comparing the early serum antibody
response of ASFV-infected pigs (NHV-p68 isolate) to three major recombinant polypeptides
(p30, p54, p72) using a multiplex fluorescent microbead-based immunoassay (FMIA). Non-
hazardous (non-infectious) antibody-positive serum for use as plate positive controls and
for the calculation of sample-to-positive (S:P) ratios was produced by inoculating pigs with a
replicon particle (RP) vaccine expressing the ASFV p30 gene. The optimized ELISA
detected anti-p30 antibodies in serum and/or oral fluid samples from pigs inoculated with
ASFV under experimental conditions beginning 8 to 12 days post inoculation. Tests on
serum (n = 200) and oral fluid (n = 200) field samples from an ASFV-free population demon-
strated that the assay was highly diagnostically specific. The convenience and diagnostic
utility of oral fluid sampling combined with the flexibility to test either serum or oral fluid on
the same platform suggests that this assay will be highly useful under the conditions for
which OIE recommends ASFV antibody surveillance, i.e., in ASFV-endemic areas and for
the detection of infections with ASFV isolates of low virulence.
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Introduction
African swine fever (ASF) is a highly contagious disease of pigs caused by a large, icosahedral,
enveloped, double-stranded DNA virus belonging to family Asfarvidiridae [1]. ASF virus
(ASFV) is listed by the World Organisation for Animal Health (OIE) as a notifiable disease
and is classified as a select agent by authorities in the United States [2]. Infection with ASF
virus (ASFV) can produce clinical signs ranging from sudden death to subacute and chronic
disease, depending on the virulence of the isolate, the affected host, dose and route of infection
[3]. ASFV is of major concern because of its high mortality rate, its severe economic impact on
affected countries, and its recent rapid geographic expansion [4]. In particular, the expansion
of ASFV within Africa and its introduction and spread across Transcaucasia, the Russian Fed-
eration, and Eastern Europe has heightened concerns for the emergence of the virus in ASFV-
free countries either through infected free-ranging European wild boar (Sus scrofa), illegal
imports of pork and other derived products or through contaminated fomites moving in global
trade networks [5,6,7].
Prevention of ASF is based on enhancing biosecurity on border controls, avoiding imports
from infected countries, and creating barriers to avoid the introduction of the virus. Having
entered a region, control and elimination relies on a timely and efficient process of ASFV
detection, laboratory confirmation, and removal of infected animals [3]. In particular, anti-
body-based surveillance is useful in ASFV-endemic areas and for incursions involving low vir-
ulence ASFV isolates [2]. In the absence of vaccine, antibodies are a definitive indication of
ASFV infection, are detectable for a prolonged period of time [4], and antibody assays are cost-
effective and highly reproducible among laboratories. Surveillance programs in the Iberian
Peninsula and Sardinia have used ASFV antibody detection in tandem with viral antigen detec-
tion, particularly for the detection of ASFV carrier animals and elucidating the epidemiological
characteristics of the epidemics, i.e., time since the virus introduction into a premises [4].
A major impediment to the implementation of active surveillance is the cost of collecting
and testing sufficient numbers of samples. Previous studies demonstrated the utility of oral flu-
ids for the detection of a variety of swine pathogens including PRRSV [8,9], porcine circovirus
type 2 [10], influenza A virus [11,12], and others [13]. In contrast to serum, oral fluid collection
requires little labor, is stress-free ("welfare-friendly") for both animals and humans, and is
more sensitive than individual pig samples for detecting infections in populations [14]. Previ-
ous research showed that ASFV antibodies could be detected in oral fluids and suggested that
oral fluids could serve as a suitable diagnostic specimen for ASFV surveillance [15]. The objec-
tive of the present study was to develop a prototype indirect ELISA capable of detecting ASFV
antibody either in serum or oral fluid specimens using safe (non-infectious) reagents, i.e., posi-
tive controls and target antigens.
Material and Methods
Experimental design
A recombinant protein 30 (p30) indirect ELISA for the detection of ASFV antibodies in either
serum or oral fluid specimens was developed. The antigen used in the ELISA was selected by
evaluating the serum antibody response of ASFV-infected pigs against three recombinant anti-
gens (p30, p54, p72) using a multiplex fluorescent microbead-based immunoassay (FMIA;
Luminex1 Corporation, Austin TX USA). Non-hazardous ASFV antibody-positive control
serum was created by inoculating pigs with a replicon particle (RP) vaccine expressing the
ASFV p30 gene (Harrisvaccines, Inc., Ames IA USA). The antibody kinetics of the optimized
ELISA were evaluated using serum and oral fluid collected over time post inoculation from
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animals (n = 17) inoculated with ASFV NHV/P68 isolate under experimental conditions. The
absence of cross-reactivity was evaluated by testing ASFV p54 and p72 antibody positive serum
generated by vaccinating pigs with RP vaccines expressing ASFV p54 and p72 genes. Diagnos-
tic specificity of the assay was evaluated using serum (n = 200) and oral fluid (n = 200) samples
from animals in commercial swine farms known to be free of ASFV infection.
Samples from ASFV-inoculated animals
ASFV NHV/P68 (NHV), a low-virulent, non-hemadsorbing, p72 genotype I isolate was used
in the in vivo studies. The virus was obtained from the European Union Reference Laboratory
for ASF [Centro de Investigación en Sanidad Animal, Instituto Nacional de Tecnología Agraria
y Alimentaria (CISA-INIA)] and was propagated and titrated as described by Carrascosa et al.
(2011) [16].
Pigs were inoculated with NHV/P68 in biosafety level 3 (BSL3) animal facilities at Centro
de Investigación en Sanidad Animal, belonging to Instituto Nacional de Investigación y Tecno-
logía Agraria y Alimentaria (INIA, Valdeolmos, Madrid, Spain) as previously described (Code
id. # ES281620002741) [15]. The studies were approved by the Dirección General del Medio
Ambiente, Consejeria de Medio Ambiente y Ordenación del territorio (Comunidad de Madrid,
Spain) and monitored by the INIA Regulatory Body for ethic and animal care (ORCEEA). The
studies were performed in accordance with EC Directive 86/609/EEC and followed the recom-
mendations provided in 2007/526/EC regarding the accommodation and care of animals used
for experimental and other scientific purposes. In case of pain or distress any action was post-
poned until normal vital constant be recovered (et seq., extraction, sampling or inoculation).
When signs of distress due to infection were evident, animals were examined daily following
endpoint criteria i.e., 1) posture of the animal: if observed for a long time (> 48 h) immobility,
or the animal cannot stand up, ataxia; 2) Severe anorexia: acute weight loss; 3) behavior: severe
seizures, or persistent loss of movements control (> 24 h); 4) appearance and presence of
abnormal secretions presence of severe bleeding in stool. Unprogrammed euthanasia was
applied when circumstances warranting the endpoint criteria were given.
In experiment 1, 9 2-month-old Landrace x Large White pigs were each IM inoculated with
a 1 ml of solution containing a virus concentration of 1 x 105 50% tissue culture infective doses
(TCID50) per ml. Serum and oral fluid samples were collected periodically from day post inoc-
ulation (DPI) 0 through 26, using standard techniques [17]. In experiment 2, 4 2-month-old
Landrace x Large White pigs were intramuscularly (IM) administered 1 ml of an inoculum
with a virus concentration of 1 x 103 TCID50 per ml and 4 animals were inoculated with 1 ml
of an inoculum containing 1 x 105 TCID50 per ml. Seroconversion was confirmed in both
experiment 1 and 2 between 8–11 DPI using the OIE-approved ELISA based on a mixture of
ASFV-derived antigens [2], and the INgezim PPA ELISA based on p72 protein (Ingenasa,
Madrid, Spain).
Candidate ASFV antigens
Three candidate recombinant antigens (p30, p54, and p72), were evaluated for use in the
ELISA. ASFV (isolate BA71V) genes p30, p54 and p72 were commercially produced (Gen-
Script, Pistacaway, NJ, USA) and cloned into a pHUE plasmid. This Escherichia coli (E. coli)
expression vector provided for the over-expression of the polypeptides as histidine (his)-tagged
ubiquitin fusion proteins [18]. The constructs were analyzed by restriction enzyme digestion
and DNA sequencing, and then transformed into E. coli BL21(DE3)pLysS (Rosetta cells) (Invi-
trogen™, Carlsbad, CA, USA) for expression. The bacterial clone was grown in Luria-Bertani
medium (Invitrogen™) containing 100 μg per ml ampicillin at 37°C. The over-expression of
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p30, p54, and p72 was induced by adding 1 mM isopropyl-β-thio-D-galactopyranoside (IPTG)
at the mid-exponential phase (A600 between 0.4–0.6) followed by 3 additional h of incubation.
Recombinant his-tagged fusion proteins p30 and p54, and his-tagged p72 over-expressed in
inclusion bodies, were purified from clarified extracts of Rosetta cells under denaturing condi-
tions (8 M urea) using a nickel-nitrilotriacetic acid (Ni-NTA) chelate affinity chromatography
kit (PrepEase1His-tagged protein purification kit, USB Corporation, Cleveland, OH, USA)
performed according to manufacturer’s instructions. Briefly, frozen pellets obtained from cul-
tures of Rosetta cells containing p30, p54, and p72 genes cloned into the pHUE expression vec-
tor were thawed and resuspended in 1 × LEW lysis buffer (USB Corporation) containing 8 M
urea (Sigma-Aldrich, St. Louis, MO, USA). Cells were lysed by sonication for 10 cycles of 20s
on ice using a Vibra-Cell™ sonicator (Sonics and Materials, New Town, CT, USA). The crude
extracts were centrifuged at 50,000 × g for 30 min at 4°C and the supernatants were purified by
Ni-NTA affinity chromatography. The purified antigens were analyzed and their apparent
molecular mass was determined by 12% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE).
Multiplex fluorescent microbead-based immunoassay (FMIA)
ELISA antigen selection was done by evaluating the serum antibody response of ASFV-inocu-
lated animals as described above (samples from ASFV-inoculated animals) against p30, p54, and
p72 using a multiplex fluorescent microbead-based immunoassay (FMIA; Luminex Corp., Aus-
tin, TX, USA). The FMIA was performed as described elsewhere [19]. In brief, recombinant anti-
gens p30, p54, and p72 were purified under denaturing conditions and then precipitated to
remove the urea and exchange the buffer. One volume of 8M urea buffer containing either
recombinant p30, p54, or p72 polypeptides was added to nine volumes of ice-cold 100% ethanol,
mixed gently, incubated for 2 h at -20°C, and centrifuged (90 s at 7,000 × g). Thereafter, the pellet
was washed with nine volumes of 90% ice-cold ethanol and resuspended in 1X phosphate buff-
ered saline (PBS) with 0.1% SDS. The covalent coupling of microbead sets, individually identifi-
able by unique fluorescence, to purified recombinant p30, p72, and p54 polypeptides was
performed as previously reported using a two-step carbodiimide reaction [19,20]. A total of 50 μg
(50 μg antigen per 5 x 106 beads) of each antigen [p30 (bead region 12), p54 (bead region 20),
and p72 (bead region 64)] were coupled to 2.5 x 106 carboxilated fluorescent microbeads. To per-
form the 3-plex FMIA, antigen-coupled beads were sonicated, mixed by vortexing, and diluted in
a storage buffer to a final concentration of ~2,500 beads per well for each recombinant protein.
Serum samples were diluted 1:25 in assay buffer (0.1 M PBS, 10% goat serum [Gibco1, Life
Technologies, Grand Island, NY, USA], 0.05% Tween-20, pH 7.2) and mixed with 50 μl of the
bead suspension in each well (Bio-Plex Pro™ flat bottom plates, Bio-Rad Laboratories Inc., Hercu-
les, CA, USA). The plates were incubated for 30 min on a micro plate shaker (VWR1, Radnor,
PA, USA) set at 500 rpm and washed three times with 200 μl of 0.1 M PBS containing 0.05%
Tween-20 (PBST). This and other incubations were performed at ~22°C in a dark environment.
Next, 50 μl of biotin-labelled Protein A (Sigma-Aldrich, St Louis, MO, USA) in assay buffer
(1:100 dilution) was added to each well, followed by a 30 min incubation. After plates were
washed 3 times with PBST, 50 μl of streptavidin phycoerythrin (SAPE; 2.5 μg/ml in assay buffer)
was added to each well and the plates incubated for 30 min. After an additional wash step, the
beads were resuspended in 100 μl of assay buffer and analyzed using a dual-laser Bio-Plex1 200
instrument (Bio-Rad Laboratories, Inc.). Events were gated to exclude doubles and other aggre-
gates (Bio-Plex Manager™ software 6.0, Bio-Rad Laboratories, Inc.).
The data were estimated from at least 50 beads and reported as median fluorescent intensi-
ties (MFI). Two "background wells" (coupled microspheres incubated with serum diluent in
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the absence of sample) were included on each plate to measure non-specific binding of the
detector. The MFI response was corrected by subtracting the background well signal (the mean
of the two wells) from the signal obtained for each individual sample.
Recombinant p30 indirect ELISA
ELISA conditions, e.g., p30 coating and blocking conditions, sample and conjugate dilutions,
buffers, and incubation times were concurrently optimized for antibody detection in serum
and oral fluid specimens. The reagents used in the assay, i.e., sample and conjugate diluents,
substrate, stop solution, and wash solution, were provided by a commercial entity (IDEXX Lab-
oratories, Inc., Westbrook, ME USA).
To prepare plates, 96-well microtitration plates (Nunc, Thermo Fisher Scientific, Agawam,
MA, USA) were manually coated with 100 μl of p30 polypeptide per well at a concentration of
5 μg per ml in phosphate-buffered saline (PBS) pH 7.4 (Gibco1, Life Technologies) and were
then incubated at 4°C overnight. Following incubation, plates were washed 5 times, blocked
with a solution (300 μl per well) containing 1% bovine serum albumin (Jackson ImmunoRe-
search Inc.), and incubated at 25°C for 2 h. Plates were then dried at 37°C for 4 h and stored at
4°C in a sealed bag with desiccant packs. Plate lots with a coefficient of variation10% were
rejected.
ELISA negative and positive plate controls. A bank of serum and oral fluid samples con-
taining antibodies specific for ASFV p30, p54, and p72 was established by vaccinating pigs with
replicon particle (RP) vaccines expressing genes for ASFV p30, p54, and/or p72 antigens (Har-
risvaccines Inc., Ames, IA, USA).
Replicon particles are single-cycle RNA vectors capable of expressing foreign antigens in
vivo [21]. To prepare RP vaccines, ASFV (strain BA71V) genes p30, p54, and p72 were de novo
synthesized, codon-optimized for expression in swine (GenScript), and then modified by PCR
to add appropriate restriction sites and a C-terminal 6x-histidine tag sequence. The modified
genes were cloned into a replicon vector plasmid derived from Venezuelan equine encephalitis
virus (VEEV) strain TC-83 [22]. Thereafter, replicon vector and TC-83 helper plasmids were
transcribed in vitro using T7 RNA polymerase [22]. RPs were generated by electroporation of
p30, p54, and/or p72 replicon RNA and structural gene helper RNAs into Vero cells. The RPs
were harvested from culture fluids and then purified by size exclusion/ionic exchange filtration
[23]. Vero cell monolayers were then infected with p30 RP, p54 RP, p72 RP or a combination
of the three. The expression of p30, p54, and p72 was confirmed by western blot analysis on
RP-infected cell lysates using anti-His monoclonal antibodies. The infectious titer of the puri-
fied bulk RPs was determined by immunofluorescence assay (IFA) and expressed as immuno-
fluorescence units (IU) per ml [22].
Thereafter, 39 12-week-old pigs were randomly allocated to one of 5 RP vaccine groups: (1)
p30 RP vaccine, (2) p54 RP vaccine, (3) p72 RP vaccine, (4) p30/54/72 RP vaccine, and (5)
unvaccinated controls. The vaccines were intramuscularly inoculated at days post vaccination
(DPV) 0 and 21 with 2 ml of a solution containing 5 x 108 IU per ml of the designated RP
except the p30/54/72 group received 2 ml of a solution containing 1.5 x 109 IU per ml. Anti-
body responses against p30, p54, and p72 were monitored over time by FMIA using pen-based
oral fluid samples (collected daily) and individual pig serum samples (collected DPV 0, 6, 14,
21, and 28). At DPV 28, all animals were humanely euthanized and exsanguinated. The har-
vested serum was pooled by RP vaccine group, processed, and stored at -80°C. ELISA negative
and positive plate controls consisted of pooled sera from p30 RP-vaccinated and non-vacci-
nated groups, respectively.
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ELISA procedure. Serum samples were diluted 1:100 and oral fluid samples were diluted
1:2, after which plates were loaded with 100 μl of diluted sample per well. Antibody-positive
and negative controls were run in duplicate on each ELISA plate. Plates were incubated at 25°C
for 1 h and then washed 5 times. Thereafter, 100 μl of peroxidase conjugated goat anti-swine
IgG (H+L) antibody (Jackson ImmunoResearch, Inc.) diluted 1:60,000 for serum or 1:25,000
for oral fluid was added to each well and the plates incubated at 25°C for 30 min. After a wash-
ing step, the peroxidase reaction was visualized by adding 100 μl of tetramethylbenzidine-
hydrogen peroxide (TMB) substrate solution per well. Plates were incubated at room tempera-
ture for 10 min, 50 μl of stop solution was added, and the plates were read immediately thereaf-
ter. Reactions were measured as optical density (OD) at 450 nm using an ELISA plate reader
(Biotek1 Instruments Inc., Winooski, VT) operated with commercial software (GEN5TM,
Biotek1 Instruments Inc.). Serum and oral fluid antibody responses were expressed as sam-
ple-to-positive (S/P) ratios:
S=P ratio ¼ ðsample OD negative control mean ODÞ=ðpositive control mean OD
 negative control mean ODÞ
Samples from ASFV-negative animals. The Western Hemisphere is currently recognized
as free of ASFV. Therefore, the specificity of the ELISA was evaluated using samples submitted
to the Iowa State University Veterinary Diagnostic Laboratory (Ames, Iowa USA) for routine
diagnostic testing from commercial swine herds in North America. Samples included 200
serum samples from pigs 3 to 10 weeks of age and 200 oral fluid samples from pigs 3 weeks to 7
months of age.
Analysis
Statistical analyses were performed using commercial software (SAS1 9.3, SAS1 Institute
Inc., Cary, NC).
The antigen for the ASFV indirect ELISA was selected by evaluating the serum antibody
response against p30, p54, and p 73 in 9 pigs inoculated with NHV/P68 (experiment 1) and
selecting the antigen that provided the greatest differentiation. After testing by multiplex
FMIA, the MFI serum antibody responses were analyzed using a generalized linear mixed
model with DPI as a repeated measure for each pig. Post-hoc pairwise comparisons among
p30, p54, and p72-specific responses were done at each DPI. In addition, the antigen-specific
antibody results for each DPI were compared to day 0.
The serum antibody response in pigs inoculated with replicon particle (RP) vaccines
expressing p30, p54, and/or p72 genes, was measured by FMIA and p30 indirect ELISA. The
data were analyzed using generalized linear mixed models with DPV as a repeated measure for
each pig and post hoc pairwise comparisons performed for each DPV. FMIA assay serum anti-
body FMI results were compared among 5 groups: (1) p30 RP vaccine, (2) p54 RP vaccine, (3)
p72 RP vaccine, (4) p30/54/72 RP vaccine, and (5) unvaccinated controls. For the p30 indirect
ELISA, serum and oral fluid antibody S/P results were compared among 3 groups: (1) p30 RP
vaccine, (2) p30/54/72 RP vaccine, and (3) a control group defined as unvaccinated pigs (one
pen of 4 pigs) and pigs inoculated with RP vaccines expressing ASFV p54 (one pen of 8 pigs)
or p72 (one pen of 8 pigs). Because one pen-based oral fluid sample was collected from each
treatment each day, the data were re-defined to permit statistical analysis. That is, data from
DPV 0 to 7 were classified as Week 1, data from DPV 8 to 21 as Week 2/3, and DPV 22 to 28 as
Week 4. The oral fluid p30 indirect ELISA data Week 1, 2/3, and 4 were then compared using a
one-way ANOVA. Thereafter, the serum and oral fluid p30 indirect ELISA S/P responses in 17
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pigs (experiments 1 and 2) inoculated with ASFV NHV/P68 were analyzed using a generalized
linear mixed model with DPV as a repeated measure for each pig and experiment. Post hoc
pairwise comparisons performed for each DPV.
Results
Serum antibody responses to ASFV inoculation by multiplex FMIA (Fig 1)
The reactivity of three major recombinant ASFV antigens (p30, p72 and p54) was evaluated by
testing serum samples collected between 0 and 26 DPI from 9 pigs inoculated with ASFV iso-
late NHV/P68 (experiment 1) in the multiplex FMIA. As shown in Fig 1, antibody responses
were observed over time for all 3 individual ASFV antigens (p30, p54, and p72). Comparisons
showed that p30 and p54 responses at DPI 12 were higher than DPI 0 (p< 0.0001) and DPI
6 (p< 0.0001) responses. The response against p72 was slower than p30 and p54 responses,
however, p72 FMIA responses at DPI 12 were significantly higher than DPI 0 (p = 0.0322), as
were responses at DPI 14 (p< 0.0001). In particular, the markedly higher serum IgG median
fluorescent intensity against p30 relative to p54 and p72 indicated that this antigen was the best
candidate for the development of a dual matrix serum/oral fluid indirect ELISA.
Serum antibody responses to RP vaccines by multiplex FMIA (Table 1)
Analysis of the multiplex FMIA protein-specific serum antibody responses in RP vaccine
groups (1) p30 RP vaccine, (2) p54 RP vaccine, (3) p72 RP vaccine, (4) p30/54/72 RP vaccine,
Fig 1. ASFVmultiplex fluorescent microbead-based immunoassay (FMIA) sample-to-positive (S/P) serum
antibody response (mean, SE) against three recombinant antigens (p30, p54, p72) in 9 pigs inoculated with
ASFV NHV/P68 (experiment 1).
doi:10.1371/journal.pone.0161230.g001
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and (5) unvaccinated controls found no difference in MFI responses at DPV 0 and 6
(p> 0.05). At DPVs 14, 21, and 28, the p30/54/72 RP vaccine MFI responses were significantly
higher than all other treatments (p< 0.001), except the p72 RP MFI response against p72 at
DPV 14 (p = 0.098). All homologous combinations of RP vaccine and FMIA ASFV antigen
produced higher MFI responses than heterologous combinations (p< 0.001). No differences
in MFI response were detected among heterologous combinations of RP vaccine and FMIA
antigen or negative controls (p> 0.05).
Serum (Fig 2A) and oral fluid (Fig 2B) antibody responses to RP
vaccines by p30 indirect ELISA
No difference was found in the serum S/P responses on DPI 0 or 6 (p> 0.05) among (1) p30
RP vaccine, (2) p30/54/72 RP vaccine, and (3) control groups. At DPV 14, 21, and 28, the p30
RP and p30/54/72 RP vaccine groups had significantly higher S/P responses than controls
(p< 0.0001). Further, the p30/54/72 RP vaccine produced significantly higher S/P responses
than the p30 RP vaccine on these same time points (p< 0.04).
The recombinant p30 indirect ELISA response in oral fluids is given in Fig 2B. Recollect
that, although the samples were collected daily, the data were reclassified by week to perform
the analysis. No difference was found in the oral fluid S/P responses in Week 1 (p> 0.05)
among (1) p30 RP vaccine, (2) p30/54/72 RP vaccine, and (3) control groups. At Week 2/3, the
p30/54/72 RP vaccine groups had signficantly higher S/P responses than either the p30 group
or the control group (p< 0.0003), with no difference detected between the p30 and control
groups (p> 0.05). At Week 4, the p30/54/72 RP vaccine response was higher than both the
Table 1. African swine fever virus (ASFV) antigen-specific serum antibody responses detected bymultiplex fluorescent microbead-based immu-
noassay (FMIA) in pigs inoculated with replicon particle (RP) vaccines expressing p30, p54, and/or p72 genes.
RP vaccine groupsa FMIA ASFV recombinant antigen Mean (SE) median ﬂuorescent intensity (MFI) by day post vaccination (DPV)
DPV 0b DPV 6b DPV 14c DPV 21c DPV 28c
1. p30 (8 pigs) p30 (homologous) 0.062 (0.010) 0.083 (0.010) 0.387 (0.010) 0.432 (0.010) 1.410 (0.010)
p54 0.062 (0.006) 0.065 (0.006) 0.065 (0.006) 0.065 (0.006) 0.066 (0.006)
p72 0.063 (0.007) 0.065 (0.007) 0.064 (0.007) 0.065 (0.007) 0.065 (0.007)
2. p54 (8 pigs) p30 0.059 (0.010) 0.059 (0.010) 0.061 (0.010) 0.060 (0.010) 0.062 (0.010)
p54 (homologous) 0.062 (0.006) 0.063 (0.006) 0.268 (0.006) 0.350 (0.005) 0.967 (0.006)
rp72 0.064 (0.007) 0.065 (0.007) 0.068 (0.007) 0.067 (0.007) 0.068 (0.007)
3. p72 (8 pigs) p30 0.061 (0.010) 0.061 (0.010) 0.068 (0.010) 0.067 (0.010) 0.066 (0.010)
p54 0.063 (0.006) 0.063 (0.006) 0.066 (0.006) 0.066 (0.006) 0.066 (0.006)
p72 (homologous) 0.063 (0.007) 0.070 (0.007) 0.322 (0.007) 0.392 (0.007) 1.140 (0.007)
4. p30/54/72 (4 pigs) p30 (homologous) 0.062 (0.013) 0.070 (0.013) 0.548 (0.013) 0.582 (0.013) 1.670 (0.013)
p54 (homologous) 0.064 (0.008) 0.068 (0.008) 0.351 (0.008) 0.531 (0.008) 1.179 (0.008)
p72 (homologous) 0.068 (0.010) 0.085 (0.010) 0.343 (0.010) 0.513 (0.010) 1.251 (0.010)
5. Unvaccinated controls (4 pigs) p30 0.069 (0.013) 0.069 (0.013) 0.062 (0.015) 0.063 (0.015) 0.062 (0.015)
p54 0.068 (0.008) 0.068 (0.008) 0.064 (0.010) 0.064 (0.001) 0.065 (0.001)
p72 0.068 (0.010) 0.067 (0.010) 0.064 (0.012) 0.067 (0.012) 0.068 (0.012)
a Pigs were intramuscularly inoculated at 0 and 21 DPV with 2 ml of a solution containing 5 x 108 IU per ml of the designated RP except the p30/54/72 group
received 2 ml of a solution containing 1.5 x 109 IU per ml.
b DPV 0, 6: No difference in response was detected among groups (p > 0.05).
c DPV 14, 21, 28: Group 4 responses were signiﬁcantly higher than all other treatments (p < 0.001), except the Group 3 homologous response at DPV 14
(p = 0.098). All homologous (RP vaccine-FMIA antigen) combinations produced higher responses than heterologous combinations (p < 0.001). No
differences in response were detected among heterologous RP vaccine-FMIA antigen combinations and negative controls (p > 0.05).
doi:10.1371/journal.pone.0161230.t001
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Fig 2. ASFV recombinant p30 antibody ELISA sample-to-positive (S/P) responses in (2A) individual pig serum
(mean, SE) and (2B) pen-based oral fluid samples following inoculation with replicon particle (RP) vaccines
expressing ASFV p30 or a combination of ASFV p30/54/72. Controls were defined as unvaccinated pigs (one pen of 4
pigs) and pigs inoculated with RP vaccines expressing ASFV p54 (one pen of 8 pigs) or ASFV p72 (one pen of 8 pigs). In
all cases, pigs received two doses of vaccine (days 0 and 21).
doi:10.1371/journal.pone.0161230.g002
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p30 RP and control groups (p< 0.006) and the p30 response was higher than the control
group (p = 0.0008).
Serum and oral fluid antibody responses to ASFV inoculation by p30
indirect ELISA (Fig 3)
Analyses of ASFV p30 antibody ELISA responses were performed on testing results from
serum and oral fluid samples collected from 17 pigs (experiment 1 and 2) inoculated with
ASFV isolate NHV/P68. The analysis showed that serum antibody S/P responses at DPI 6
were significantly greater than DPI 0 (p< 0.03), whereas oral fluid antibody S/P responses
were significantly greater than DPI 0 at DPI 8 and later (p< 0.001). Comparisons of serum vs.
oral fluid ELISA S/P data showed no significant differences in the response except on DPIs 12
and 18 (p 0.01).
Performance of the p30 dual-matrix indirect ELISA (Fig 4)
The diagnostic performance of the dual-matrix serum/oral fluid p30 antibody ELISA was
assessed by analyzing the distribution of ASFV recombinant p30 antibody ELISA S/P responses
in serum (n = 200) and oral fluid (n = 200) specimens of known negative ASFV status from
North American commercial pigs and serum (n = 52) and oral fluid (n = 46) collected 14
days following inoculation with ASFV NHV/P68. The box-and-whisker plots shown in Fig 4
visually describe the distribution of the data. Analysis of the data provided the estimates of S/P
Fig 3. ASFV recombinant p30 antibody ELISA serum-to-positive (S/P) responses in serum (mean, SE) and oral
fluid (mean, SE) samples from 17 pigs (experiments 1 and 2) inoculated with ASFV NHV/P68.
doi:10.1371/journal.pone.0161230.g003
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means (95% confidence intervals): negative serum (mean S/P 0.23, 95% CI: 0.21, 0.25), negative
oral fluid (mean S/P 0.41, 95% CI: 0.39, 0.42), positive serum (mean S/P 3.80, 95% CI: 3.56,
4.00), and positive oral fluids (mean S/P 4.41, 95% CI: 3.65, 5.16).
Discussion
The current epidemiological situation of ASF in the Caucasus and the Russian Federation
including the incursion of the disease in Belarus, Ukraine, and Eastern Europe, indicates that
further geographic spread of ASF is likely to occur [3]. Given this scenario, continuous
improvements in ASF diagnosis and surveillance are critical for disease containment. In
endemic situations, recovered ASFV carrier pigs and persistently infected wild pigs constitute
the biggest challenge in controlling the disease. Pigs that survive natural infection develop anti-
bodies against ASFV from 7 to 10 days after infection that are detectable for a prolonged period
of time [7,24]. Therefore, ASFV surveillance is vital but a simpler, more cost-effective approach
must be developed based on efficient, low-cost specimen collection, accurate diagnostic testing,
and no-infectious material.
Current ASFV antibody-based tests approved by the World Organization for Animal
Health (OIE) are based on the use of serum as a test specimen and live virus as antigen, which
necessitates level 3 biosafety facilities for propagation and handling of the live virus [2]. Anti-
body-based immunoassays based on recombinant antigens obviate the risk of handling live
virus and facilitate high-throughput testing [25,26,27,28]. Furthermore, it has become widely
recognized that oral fluid specimens are a viable option to serum, are easily collected, and pro-
vide diagnostic information equivalent or superior to serum samples [8,14]. An earlier study
Fig 4. Distribution of ASFV recombinant p30 antibody ELISA serum-to-positive (S/P) responses in (A) serum
(n = 200) and (B) oral fluid (n = 200) specimens from North American commercial pigs and (C) serum (n = 52) and
(D) oral fluid (n = 46) collected 14 days following inoculation with ASFV NHV/P68.
doi:10.1371/journal.pone.0161230.g004
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showed that ASFV antibodies could be detected in oral fluids and suggested that oral fluids
could serve as a suitable specimen for ASFV surveillance [15]. Therefore, the aim of this study
was to develop an ASFV dual matrix serum/oral fluid antibody ELISA based on non-infectious
material and amenable to high-throughput testing.
Previous reports indicated ASFV proteins p30, p54, and p72 as likely diagnostic antigens
[28,29]. To select the best candidate antigen, spectrally-distinguishable fluorescent beads-based
xMAPTM technology (Luminex1) were used as a screening tool to evaluate the reactivity of
the ASFV recombinant p30, p54 and p72 proteins simultaneously in a single reaction, as
described elsewhere [30]. Results on experimental samples showed that p30 provided the best
diagnostic performance. These results corroborate previous reports on the utility of p30-based
immunoassays for early detection of ASFV antibodies [27]. Therefore, p30 was selected for use
in the ASFV dual-matrix serum/oral fluid indirect ELISA.
Antibodies against attenuated ASFV isolate NHV/P68 were detected by p30 indirect ELISA
in either serum or oral fluid specimens run on the same plate with approximately equivalent
performance, yet the assay was highly specific for both specimen types. These results represent
an improvement in assay performance for oral fluid specimens compared to our previous
report [15]. Notably, oral fluid antibodies were detected by this assay as early as 8 DPI, which is
equivalent to the performance reported for the OIE indirect serum antibody ELISA [15]. These
data showed that the p30 indirect ELISA could be useful in detecting ASFV-infected animals,
even as early as 8 DPI. In the current study, it was not possible to estimate the optimal S/P cut-
off and associated diagnostic sensitivity and specificity for the ELISA because of the availability
of a limited number of known ASFV-positive specimens. However, testing of 200 serum sam-
ples and 200 oral fluid samples from known negative animals suggested that the test is highly
diagnostically specific. Test specificity is of critical importance because false-positive results
rapidly erode confidence in surveillance and eradication programs [27].
ASFV-antibody negative and antibody-positive plate controls are mandatory as part of the
ELISA test development, but sera from ASFV-infected pigs are not an option in a commercial
ELISA because it is a potential biohazard [4,31,32]. In this study, RP vaccines expressing ASFV
p30, p54, or p72 genes were used to generate a bank of ASFV-antibody positive and negative
oral fluid and serum samples for use as internal controls, thereby avoiding the use of infectious
ASFV [22]. Data presented here demonstrate that RP expressing genes inserted in the alpha-
virus vector, i.e., p30, p54, p72, or a combination of the three, could induce dose-dependent
immune responses specific to ASFV.
Overall, the results showed that the p30 indirect ELISA detects ASFV antibodies at early
stages post-exposure in either oral fluid or serum samples. Given the increased surveillance
efficiency provided by oral fluid sampling [14] and the ability to corroborate results using
serum samples, the ASFV p30 antibody would be a highly useful under conditions that warrant
ASFV surveillance.
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